Immuneering CEO buys 2,400 shares in open market
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immuneering Corp director and CEO Benjamin J. Zeskind reported buying 2,400 shares of Class A Common Stock in an open-market purchase on June 23, 2026 at a weighted average price of $4.5617 per share, with individual trade prices ranging from $4.55 to $4.59 through a broker-dealer.
After this transaction, he directly owns 2,315,252 shares of Immuneering’s Class A Common Stock. A separate entry shows 894,927 shares held indirectly by the Benjamin J. Zeskind 2020 Family Trust, where his spouse Lisa Schwartz serves as sole trustee.
Insider Trade Summary
Net Buyer: 2,400 shares
Net Buy
2 txns
Insider
Zeskind Benjamin J.
Role
PRESIDENT AND CEO
Bought
2,400 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Class A Common Stock | 2,400 | $4.5617 | $11K |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 2,315,252 shares (Direct);
Class A Common Stock — 894,927 shares (Indirect, See Foonote)
Footnotes (2)
- F1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
- F2. Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.
Key Figures
Shares purchased: 2,400 shares
Weighted average purchase price: $4.5617 per share
Direct holdings after transaction: 2,315,252 shares
+1 more
4 metrics
Shares purchased
2,400 shares
Class A Common Stock, open-market on June 23, 2026
Weighted average purchase price
$4.5617 per share
Open-market trades between $4.55 and $4.59
Direct holdings after transaction
2,315,252 shares
Class A Common Stock held directly by CEO
Indirect trust holdings
894,927 shares
Held by Benjamin J. Zeskind 2020 Family Trust
Key Terms
open-market purchase, weighted average purchase price, broker-dealer, Family Trust
4 terms
open-market purchase financial
"purchased 2,400 Immuneering Class A Common shares at a weighted average price in an open-market transaction"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"The price reported in this column reflects the weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
broker-dealer financial
"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59."
A broker-dealer is a licensed firm or individual that both executes trades on behalf of clients (acting as a broker) and buys or sells securities for its own account (acting as a dealer). Investors care because broker-dealers provide the plumbing of markets — they place orders, hold or move cash and securities, offer research or advice, and their stability and fees directly affect trade execution, costs, and the safety of client funds; think of them as a combined travel agent and taxi for your investments.
Family Trust financial
"Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Immuneering (IMRX) report for CEO Benjamin Zeskind?
Immuneering reported that CEO Benjamin J. Zeskind bought 2,400 shares of Class A Common Stock. The shares were acquired in an open-market transaction on June 23, 2026, as disclosed in a Form 4 insider trading report.
What are Benjamin Zeskind’s direct Immuneering (IMRX) holdings after this Form 4 transaction?
Following the reported purchase, Benjamin J. Zeskind directly holds 2,315,252 shares of Immuneering’s Class A Common Stock. This figure reflects his direct ownership after the 2,400-share open-market acquisition on June 23, 2026.
What indirect Immuneering (IMRX) holdings are reported for Benjamin Zeskind?
The Form 4 shows 894,927 Immuneering Class A shares held indirectly by the Benjamin J. Zeskind 2020 Family Trust. The filing explains that Lisa Schwartz, Dr. Zeskind’s spouse, serves as the sole trustee of this family trust.
How was the weighted average purchase price calculated for the Immuneering (IMRX) insider trade?
The weighted average purchase price of $4.5617 per share reflects multiple trades executed between $4.55 and $4.59. The filing states that full trade-by-trade details are available from the reporting person upon request by SEC staff.
AI-generated analysis. How Rhea-AI works. Not financial advice.
